Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT

LF Tietze, K Schmuck - Current pharmaceutical design, 2011 - ingentaconnect.com
The treatment of cancer with common anti-proliferative agents generally suffers from an
insufficient differentiation between normal and malignant cells which results in extensive …
被引用次数：110 相关文章

[引用][C] Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT

LF Tietze, K Schmuck - Current Pharmaceutical Design, 2011 - cir.nii.ac.jp
Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす …

Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.

LF Tietze, K Schmuck - Current Pharmaceutical Design, 2011 - europepmc.org
The treatment of cancer with common anti-proliferative agents generally suffers from an
insufficient differentiation between normal and malignant cells which results in extensive …

Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT

LF Tietze, K Schmuck - 2011 - publications.goettingen-research …
The treatment of cancer with common anti-proliferative agents generally suffers from an
insufficient differentiation between normal and malignant cells which results in extensive …

[引用][C] Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT

LF TIETZE, K SCHMUCK - Current pharmaceutical design …, 2011 - pascal-francis.inist.fr
Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …

Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT

LF Tietze, K Schmuck - Current pharmaceutical design, 2011 - pubmed.ncbi.nlm.nih.gov
The treatment of cancer with common anti-proliferative agents generally suffers from an
insufficient differentiation between normal and malignant cells which results in extensive …

[引用][C] Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT

LF TIETZE, K SCHMUCK - Current pharmaceutical design, 2011 - Bentham